This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Voluven

Fresenius SE

Drug Names(s): hetastarch 130/0.4, HES 130/0.4, hydroxyethyl starch 130/0.4

Description: Voluven contains 6% hydroxyethyl starch in a colloidal 0.9% sodium chloride solution. It expands plasma volume when administered intravenously.

Hydroxyethyl starch is a derivative of thin boiling waxy corn starch. Substitution of hydroxyethyl groups on the glucose units of the polymer reduces the normal degradation by alpha-amylase in the body. The low molar substitution (0.4, or 40 hydroxyethyl groups for every 100 glucose units) is the main pharmacological determinant for the beneficial effects of Voluven on pharmacokinetics, intravascular volume and hemodilution. To describe the molecular weight and molar substitution characteristics of the hydroxyethyl starch in Voluven, the compound is designated as hydroxyethyl starch 130/0.4 (the mean molecular weight is 130,000 daltons).


Voluven News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug